Cycling toward elimination of leukemic stem cells.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. Selective antisense oligonucleotide inhibition of human IRF4 prevents malignant myeloma regeneration via cell cycle disruption.Cell stem cell · 2021
   Article
2. Case Report: Rechallenge With BRAF and MEK Inhibitors in Metastatic Melanoma: A Further Therapeutic Option in Salvage Setting?Frontiers in oncology · 2021
   Article
3. Genetic Heterogeneity and Clonal Evolution of Tumor Cells and their Impact on Precision Cancer Medicine.Journal of leukemia (Los Angeles, Calif.) · 2013
   Article
4. Cancer drug pan-resistance: pumps, cancer stem cells, quiescence, epithelial to mesenchymal transition, blocked cell death pathways, persisters or what?Open biology · 2012
   Review
5. Clonal evolution in cancer.Nature · 2012
   Review

Corrections and comments

• Comment on
  Induction of cell cycle entry eliminates human leukemia stem cells in a mouse model of AML.2010

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract